At our institution, we generally administer 2 doses of prophylactic IT cytarabine for patients with AML and one or more high-risk features: WBC ≥ 50 × 109/L, elevated LDH, and/or a FLT3-ITD mutation. The gene discussed is FLT3; the disease is acute myeloid leukemia.